Cullen Capital Management’s AbbVie ABBV Stock Holding History

Cullen Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.8M	Buy	7,152 +5,715	+398%	+$1.23M	0.02%	116
2026 Q1	$313K	Sell	1,437 -560	-28%	-$124K	﹤0.01%	190
2025 Q4	$456K	Buy	1,997 +750	+60%	+$171K	0.01%	181
2025 Q3	$289K	Hold	1,247	–	–	﹤0.01%	196
2025 Q2	$231K	Sell	1,247 -1,095	-47%	-$204K	﹤0.01%	194
2025 Q1	$491K	Sell	2,342 -1,430	-38%	-$278K	0.01%	156
2024 Q4	$670K	Hold	3,772	–	–	0.01%	164
2024 Q3	$745K	Hold	3,772	–	–	0.01%	141
2024 Q2	$647K	Hold	3,772	–	–	0.01%	135
2024 Q1	$687K	Buy	3,772 +298	+9%	+$51.4K	0.01%	127
2023 Q4	$538K	Buy	3,474 +234	+7%	+$34.1K	0.01%	155
2023 Q3	$483K	Sell	3,240 -192	-6%	-$28.2K	0.01%	140
2023 Q2	$462K	Hold	3,432	–	–	﹤0.01%	234
2023 Q1	$547K	Sell	3,432 -88	-3%	-$13.5K	0.01%	202
2022 Q4	$569K	Hold	3,520	–	–	0.01%	154
2022 Q3	$472K	Buy	3,520 +280	+9%	+$40.2K	0.01%	220
2022 Q2	$496K	Hold	3,240	–	–	0.01%	219
2022 Q1	$525K	Sell	3,240 -369	-10%	-$53.6K	﹤0.01%	216
2021 Q4	$489K	Buy	+3,609	New	+$426K	﹤0.01%	232
2021 Q3	–	Sell	-3,525	Closed	-$397K	–	270
2021 Q2	$397K	Buy	3,525 +9	+0.3%	+$1.01K	﹤0.01%	226
2021 Q1	$381K	Buy	+3,516	New	+$376K	﹤0.01%	228

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cullen Capital Management's ABBV Position: Q2 2026 in Review

Cullen Capital Management increased its AbbVie (ABBV) stake by 398% in Q2 2026, buying an estimated $1.23M and bringing the position to 7,152 shares worth $1.8M. The position accounts for 0.02% of the portfolio, ranked #116.

Cullen Capital Management first reported a position in ABBV in Q1 2021 and has held it in 21 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Cullen Capital Management held 7,152 shares of AbbVie worth $1.8M as of Q2 2026.
Cullen Capital Management bought 5,715 AbbVie shares in Q2 2026, an estimated $1.23M.
AbbVie made up 0.02% of Cullen Capital Management's portfolio in Q2 2026, its #116 holding.
Cullen Capital Management first reported a position in AbbVie in Q1 2021 and has held it in 21 quarters since.
4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cullen Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.